{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T20:24:17Z","timestamp":1794428657523,"version":"4.9.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T00:00:00Z","timestamp":1763164800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["ICI20\/00022"],"award-info":[{"award-number":["ICI20\/00022"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["RD24\/0014\/0003"],"award-info":[{"award-number":["RD24\/0014\/0003"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["RD21\/0017\/0030"],"award-info":[{"award-number":["RD21\/0017\/0030"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["RD24\/0014\/0016"],"award-info":[{"award-number":["RD24\/0014\/0016"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI21\/00426"],"award-info":[{"award-number":["PI21\/00426"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["RD21\/0017\/0020"],"award-info":[{"award-number":["RD21\/0017\/0020"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023479","name":"CRIS Cancer Foundation","doi-asserted-by":"publisher","award":["2024\/0031"],"award-info":[{"award-number":["2024\/0031"]}],"id":[{"id":"10.13039\/501100023479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jcyt.2025.07.009","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T09:46:10Z","timestamp":1763631970000},"page":"101968","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["GMP-compliant manufacturing of allogeneic peripheral blood CAR-NK cells for the treatment of acute myeloid leukemia"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7321-7161","authenticated-orcid":false,"given":"Laura","family":"C\u00f3rdoba-Espejo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"S\u00e1nchez-Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5345-7990","authenticated-orcid":false,"given":"Almudena","family":"Garc\u00eda-Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0723-2993","authenticated-orcid":false,"given":"Raquel","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4059-8839","authenticated-orcid":false,"given":"Alejandra","family":"Ortiz-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8504-2842","authenticated-orcid":false,"given":"Daniel","family":"Gil-Al\u00f3s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"del Moral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0697-188X","authenticated-orcid":false,"given":"Adri\u00e1n","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Sanjurjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"L\u00f3pez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6694-1119","authenticated-orcid":false,"given":"Unai","family":"Perpi\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6829-7670","authenticated-orcid":false,"given":"Josep M.","family":"Canals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean A.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Daniel J.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5424-5543","authenticated-orcid":false,"given":"Paula","family":"R\u00edo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Liz","family":"Paciello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Valeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Leivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7908-0063","authenticated-orcid":false,"given":"Joaqu\u00edn","family":"Mart\u00ednez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2025.07.009_bib0001","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0002","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0003","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0004","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0005","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0006","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti\u2013B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0007","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjh.17544","article-title":"Graft-versus-host disease risk after chimeric antigen receptor T-cell therapy: the diametric opposition of T cells","volume":"195","author":"Sanber","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0008","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0009","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0010","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0140-6736(24)02462-0","article-title":"Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial","volume":"405","author":"Ghobadi","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0011","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-025-01669-3","article-title":"First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer","volume":"18","author":"Shapiro","year":"2025","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0012","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1250051","article-title":"Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma","volume":"5","author":"Leivas","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0013","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s13045-022-01376-3","article-title":"Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia","volume":"15","author":"Caruso","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0014","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41467-019-13880-1","article-title":"Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy","volume":"11","author":"Sheih","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0015","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/14653240902807034","article-title":"Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells","volume":"11","author":"Berg","year":"2009","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0016","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3390\/cancers13030577","article-title":"Optimizing the procedure to manufacture clinical-grade NK cells for adoptive immunotherapy","volume":"13","author":"Fern\u00e1ndez","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0017","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jcyt.2024.10.006","article-title":"Optimizing the procedure for manufacturing clinical-grade genetically manipulated natural killer cells for adoptive immunotherapy","volume":"27","author":"Lin","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0018","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1089\/hum.2017.157","article-title":"Optimization of human NK cell manufacturing: fully automated separation, improved ex vivo expansion using IL-21 with autologous feeder cells, and generation of anti-CD123-CAR-expressing effector cells","volume":"28","author":"Kl\u00f6\u00df","year":"2017","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0019","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1089\/hgtb.2019.039","article-title":"Development of automated separation, expansion, and quality control protocols for clinical-scale manufacturing of primary human NK cells and alpharetroviral chimeric antigen receptor engineering","volume":"30","author":"Oberschmidt","year":"2019","journal-title":"Hum Gene Ther Methods"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0020","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jcyt.2015.03.611","article-title":"Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy","volume":"17","author":"Granzin","year":"2015","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0021","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/cite.201200175","article-title":"Integrated clinical scale manufacturing system for cellular products derived by magnetic cell separation, centrifugation and cell culture","volume":"85","author":"Apel","year":"2013","journal-title":"Chem Ing Tech"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0022","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.3389\/fimmu.2019.02361","article-title":"GMP-compliant manufacturing of NKG2D CAR memory T cells using CliniMACS prodigy","volume":"10","author":"Fern\u00e1ndez","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0023","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3389\/fimmu.2020.00482","article-title":"Point-of-care CAR T-cell production (ARI-0001) using a closed semi-automatic bioreactor: experience from an academic phase I clinical trial","volume":"11","author":"Castella","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0024","doi-asserted-by":"crossref","first-page":"5724","DOI":"10.1182\/blood.V128.22.5724.5724","article-title":"CAR-T cell production using the CliniMACS\u00ae prodigy system","volume":"128","author":"Zhu","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0025","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41409-022-01866-5","article-title":"Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy\u00ae: real-world experience and cost analysis in India","volume":"58","author":"Palani","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.839783","article-title":"GMP-compliant manufacturing of TRUCKs: CAR T cells targeting GD(2) and releasing inducible IL-18","volume":"13","author":"Glienke","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0027","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jcyt.2017.09.005","article-title":"Closed-system manufacturing of CD19 and dual-targeted CD20\/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center","volume":"20","author":"Zhu","year":"2018","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0028","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-76791-2","article-title":"Automated and closed clinical-grade manufacturing protocol produces potent NK cells against neuroblastoma cells and AML blasts","volume":"14","author":"Jahan","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0029","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40164-025-00633-8","article-title":"The clinical landscape of CAR NK cells","volume":"14","author":"J\u00f8rgensen","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0030","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/s41409-023-02180-4","article-title":"Manufacturing of primary CAR-NK cells in an automated system for the treatment of acute myeloid leukemia","volume":"59","author":"Albinger","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0031","doi-asserted-by":"crossref","first-page":"ltab018","DOI":"10.1093\/immadv\/ltab018","article-title":"A summary of current NKG2D-based CAR clinical trials","volume":"1","author":"Curio","year":"2021","journal-title":"Immunother Adv"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111299","article-title":"Targeting the NKG2D\/NKG2D-L axis in acute myeloid leukemia","volume":"137","author":"Wu","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0033","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/S2352-3026(22)00378-7","article-title":"CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial","volume":"10","author":"Sallman","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0034","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma","volume":"7","author":"Baumeister","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"Supplement 1","key":"10.1016\/j.jcyt.2025.07.009_bib0035","doi-asserted-by":"crossref","first-page":"6808","DOI":"10.1182\/blood-2023-187722","article-title":"NKX101, an allogeneic off-the-shelf CAR NK cell therapy targeting NKG2D-Ls, has potent anti-leukemic activity alone or in combination with Ara-C","volume":"142","author":"Cho","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0036","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030264","article-title":"Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells","volume":"7","author":"Denman","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0037","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1089\/hum.2012.143","article-title":"Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition","volume":"24","author":"Song","year":"2013","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0038","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1128\/JVI.72.11.8463-8471.1998","article-title":"A third-generation lentivirus vector with a conditional packaging system","volume":"72","author":"Dull","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0039","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41408-021-00537-w","article-title":"NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma","volume":"11","author":"Leivas","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0040","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/s43018-025-00940-3","article-title":"Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory\/relapsed large B cell lymphoma: a phase 1 trial","volume":"6","author":"Lei","year":"2025","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0041","article-title":"Scalable process development of NK and CAR-NK expansion in a closed bioreactor","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2025.07.009_bib0042","doi-asserted-by":"crossref","first-page":"e1507","DOI":"10.1002\/cti2.1507","article-title":"Optimisation of a primary human CAR-NK cell manufacturing pipeline","volume":"13","author":"Pfefferle","year":"2024","journal-title":"Clin Transl Immunol"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925008060?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925008060?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T07:14:53Z","timestamp":1781334893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324925008060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1465324925008060"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.07.009","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GMP-compliant manufacturing of allogeneic peripheral blood CAR-NK cells for the treatment of acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Cell & Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101968"}}